Page last updated: 2024-12-07
rb 104
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
RB 104: potent inhibitor of EC 3.4.24.11; used to detect nanogram quantities of the enzyme by inhibitor gel electrophoresis; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 132708 |
MeSH ID | M0203808 |
Synonyms (9)
Synonym |
---|
benzenepropanoic acid, 4-hydroxy-alpha-(2-((3-(hydroxyamino)-3-oxo-1-(phenylmethyl)propyl)amino)-2-oxoethyl)-3-iodo- |
rb104 |
145253-48-1 |
rb-104 |
2-((3-iodo-4-hydroxy)phenylmethyl)-4-n-(3-(hydroxyamino-3-oxo-1-phenylmethyl)propyl)amino-4-oxobutanoic acid |
rb 104 |
4-[[4-(hydroxyamino)-4-oxo-1-phenylbutan-2-yl]amino]-2-[(4-hydroxy-3-iodophenyl)methyl]-4-oxobutanoic acid |
4-hydroxy-4-{[4-hydroxy-4-(hydroxyimino)-1-phenylbutan-2-yl]imino}-2-[(4-hydroxy-3-iodophenyl)methyl]butanoic acid |
DTXSID10932545 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (7)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 6 (85.71) | 18.2507 |
2000's | 1 (14.29) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 26.66
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (26.66) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |